免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 极品少妇XXXX精品少妇偷拍 | 国产美女裸体无遮挡网站 | 日本另类αv欧美另类aⅴ | 欧美精品亚洲精品日韩精品 | 69久蜜桃人妻无码精品一区 | 高清AV无码 | 嫩模升级极品大尺度HD | 粉嫩av在线 | 中国最新三级片影视 | 懂色av浪潮av色欲av熟妇 | 激情A片久久久久久app下载 | 自拍偷拍一区 | 日本www| 丰满熟女人妻中出系列 | 国产成人三级电影在线手机免费观看 | 亚欧影院| 国产精品人妻无码一区二区三区牛牛 | 国产黄色大片 | 精品人妻伦一二三区久久 | 9999精品 | 国产91清纯白嫩初高中 | 精品国产乱码久久久久夜深人妻 | AV无码电影 | 国产高清无码三级 | 高清毛片极乐 av无码破解在线观看网站 | www天堂无人区在线观看 | 午夜757| 国产91护士玉足脚交在线播放 | 在线视频一区二区 | 久久国产V一级毛多内射 | 亚色影库女厕偷拍精品 | 国产黃色A片三区三区三小说 | 国产成人电影在线 | 亚洲一区av | 一区二区三区av | 婷婷开心色 | 麻豆国产乱码精品一区二区三区四区 | 国产精品一品二区三区的使用体验 | 男人添女人全过A片 | 另类TS人妖一区二区三区 | 又粗又硬又爽18级A片 |